ZBIO · Zenas BioPharma, Inc.

Zenas BioPharma has successfully closed two concurrent public offerings, raising significant capital to bolster its financial position and fund key strategic initiatives. The $200 million convertible notes offering, with a 2.50% coupon and maturity in 2032, provides long-term financing at a relatively low interest rate, while the equity offering of 5 million shares at $20.00 per share adds approximately $93.7 million in equity capital. The structure of the convertible notes includes investor-friendly features such as conversion rights triggered by stock price performance, repurchase rights upon fundamental changes, and protections against defaults, including a special interest penalty for reporting failures. The company's stated use of proceeds is heavily focused on pipeline advancement, specifically highlighting the potential commercial launch of obexelimab for IgG4-RD—contingent on regulatory approval—and the continued clinical development of orelabrutinib for multiple sclerosis and ZB021. This capital infusion is critical for a clinical-stage biopharma company, as it extends the cash runway to fund expensive late-stage trials and potential commercialization preparations, reducing near-term financing risk. The offerings were not contingent on each other, providing flexibility, and were conducted under an existing shelf registration, indicating efficient execution. The involvement of multiple underwriters, including Jefferies, Evercore, Citigroup, and Guggenheim, suggests broad market support. Investors should note the potential equity dilution from the convertible notes, with an initial conversion rate set at 37.7358 shares per $1,000 note, and an initial maximum of 11.5 million shares issuable upon conversion, which could impact existing shareholders if conversions occur.